SAB Biotherapeutics and U.S. Army team up to treat Hantavirus

Human antibodies produced in genetically designed cows can protect against deadly diseases December 3, 2014 SAB Biotherapeutics, Inc. (SAB), a leading biopharmaceutical development company, has teamed up with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to address the potentially deadly hantavirus using a novel approach to developing protective antibodies against it. Their work, published in the November …

CDC: Early Data Suggests Potentially Severe Flu Season

December 5, 2014 Early data suggests that the current 2014-2015 flu season could be severe. The Centers for Disease Control and Prevention (CDC) urges immediate vaccination for anyone still unvaccinated this season and recommends prompt treatment with antiviral drugs for people at high risk of complications who develop flu. So far this year, seasonal influenza A H3N2 viruses have been …

CDC Responds to #CDCwhistleblower Claims

CDC Statement Regarding 2004 Pediatrics Article, “Age at First Measles-Mumps-Rubella Vaccination in Children With Autism and School-matched Control Subjects: A Population-Based Study in Metropolitan Atlanta” CDC shares with parents and others great concern about the number of children with autism spectrum disorder. CDC is committed to continuing to provide essential data on autism, search for factors that put children at …

Focus on the Children: New study finds key to improving vaccine coverage

A new report shows the power of child orientated pro-vaccine messages when trying to convince parents to vaccinate their children A new study, published earlier this month in Pediatrics, has shown that, when trying to convince parents of young children, that emphasizing the benefits to their infant is more effective than pushing home the societal benefits of the MMR (measles, Mumps, and …

Chikungunya vaccine candidate causes successful development of antibodies against the virus

Chikungunya Vaccine Candidate Passes Phase I Clinical Trials

Chikungunya vaccine candidate causes successful development of antibodies against the virus Chikungunya, a mosquito borne virus, has recently been responsible for outbreaks in the Caribbean and the Pacific. Although the disease is not usually fatal, it causes similar symptoms to a bad flu: muscle aches, malaise and headaches. However, one of the unique aspects of the virus is that it …

Pfizer's Pneumococcal Vaccine Could See a Boost in Sales After the CDC's Recommendation for Use in Older Adults

Pfizer’s Prevnar 13 Could See a $2 Billion Boost in Sales

Pfizer’s Pneumococcal Vaccine Could See a Boost in Sales After the CDC’s Recommendation for Use in Older Adults On Wednesday, Pfizer announced that the CDC’s Advisory Committee on Immunisation Practices (ACIP) has decided to recommend and promote the Prevnar 13 pneumococcal vaccine for use in adults aged 65 and up. The vaccine protects against pneumococcal diseases including pneumonia, which can …

Merck Statement regarding Role of PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) in Updated ACIP Recommendations for Pneumococcal Vaccination in Adults

13 August, 2014 Merck, known as MSD outside of the United States and Canada, today provided the following statement regarding the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices’ (ACIP’s) updated pneumococcal vaccine recommendations for adults 65 years of age and older. These recommendations call for a two vaccine regimen utilizing a dose of the …

On Wednesday, Pharmaceutical Giant Pfizer Agreed to Buy Baxter International's Vaccines Unit Worth $635 Million

Advisory Committee on Immunization Practices Votes to Recommend Pfizer’s Prevnar 13® Vaccine in Adults Aged 65 Years and Older

August 13, 2014 Pfizer Inc. today announced that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])PCV13) for routine use to help protect adults aged 65 years and older against pneumococcal disease, which includes pneumonia caused by the 13 pneumococcal serotypes included in the vaccine. …